New research indicates that people who come off new weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who stop traditional lifestyle programs.
Research printed in a leading health publication points out that while overweight people frequently drop a large proportion of their body weight while undergoing treatment, the mass returns at an average rate of 0.8 kg per month after stopping.
"Users using these treatments should be informed of the risk of fast rebound weight gain when the therapy concludes," warns expert Dr. Susan Jebb.
That rate of recovery implies a reversion to original weight within about one and a half years.
Comparing Therapies
The research, which looked at 37 of studies involving thousands of patients, compared the effects of GLP-1 agonists with older methods.
Researchers point out that people who lose weight through diet and exercise generally see a more gradual weight regain—approximately 100 grams monthly—once they finish.
Understanding the Quick Regain
Experts believe the mode of action of the jabs accounts for the amplified regain.
The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of the hormone levels far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement results in appetite is no longer kept in check, making excessive eating much more probable."
A Chronic Issue?
The NHS recommend the jabs for individuals with obesity-related health risks, alongside prescribed lifestyle changes.
A number of clinicians argue that, due to the likelihood of relapse, the treatment should be considered ongoing.
This perspective is echoed by drug manufacturers, who note that the findings "highlight the persistent nature of obesity," akin to managing conditions like high blood pressure.
User Experiences
Individuals who have discontinued the medication describe a powerful return of hunger.
"It felt as if a switch flipping and you become extremely hungry," described a patient.
The struggle is exacerbated if patients have not adopted permanent dietary or behavioural changes during therapy.
Widespread Adoption
Survey data indicate that millions of people in the UK have used these injections in the past year, with desire remaining high.
- Adoption is more common among women than males.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, experts stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent fix and lasting health benefits relies on ongoing behavioural management.
